Abstract
Despite impressive treatment advances, few options for refractory or relapsed Hodgkin Lymphoma (HL) are available and there is a need for new compounds development. A number of promising agents with multiple mechanisms of action are under investigation. Microenvironment and neoangiogenesis are acquiring a rising relevance in the pathophysiology and progression of HL. Everolimus (RAD001) is an oral antineoplastic agent derived from rapamycin, a macrocyclic lactone antibiotic, targeting the mammalian target of rapamycin (mTOR). Although the importance of mTOR signaling in the deregulated cell growth of human neoplastic cells has been recognized, this pathway is also emerging as a key regulator of the tumor response to hypoxia, as well as endothelial and stromal cells function, thereby regulating neoangiogenesis. Furthermore, mTOR plays an important role in anticancer drug resistance. The actions of everolimus within the mTOR pathway in HL result in decreased protein synthesis and cell cycle arrest, as well as in decreased angiogenesis. Everolimus has shown preliminary evidence of efficacy as a single-agent in heavily pretreated relapsed/refractory HL, with an overall fair safety profile. The purpose of this review is to discuss the employment of everolimus as an antiproliferative and antiangiogenic agent in HL and to report the critical role of the mTOR pathway and angiogenesis in this malignancy.
Keywords: Everolimus, refractory Hodgkin Lymphoma, relapsed Hodgkin Lymphoma, mTOR inhibitors, mTORC1, microenvironment, angiogenesis, microvessel density, HIF-1a, VEGF, PI3K/Akt pathway, Hodgkin Lymphoma progression, Hodgkin Lymphoma pathogenesis, stromal cells
Current Medicinal Chemistry
Title: mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma
Volume: 19 Issue: 7
Author(s): A. Guarini, C. Minoia, M. Giannoccaro, A. Rana, A. Iacobazzi, A. Lapietra, A. Raimondi, N. Silvestris, C. D. Gadaleta and G. Ranieri
Affiliation:
Keywords: Everolimus, refractory Hodgkin Lymphoma, relapsed Hodgkin Lymphoma, mTOR inhibitors, mTORC1, microenvironment, angiogenesis, microvessel density, HIF-1a, VEGF, PI3K/Akt pathway, Hodgkin Lymphoma progression, Hodgkin Lymphoma pathogenesis, stromal cells
Abstract: Despite impressive treatment advances, few options for refractory or relapsed Hodgkin Lymphoma (HL) are available and there is a need for new compounds development. A number of promising agents with multiple mechanisms of action are under investigation. Microenvironment and neoangiogenesis are acquiring a rising relevance in the pathophysiology and progression of HL. Everolimus (RAD001) is an oral antineoplastic agent derived from rapamycin, a macrocyclic lactone antibiotic, targeting the mammalian target of rapamycin (mTOR). Although the importance of mTOR signaling in the deregulated cell growth of human neoplastic cells has been recognized, this pathway is also emerging as a key regulator of the tumor response to hypoxia, as well as endothelial and stromal cells function, thereby regulating neoangiogenesis. Furthermore, mTOR plays an important role in anticancer drug resistance. The actions of everolimus within the mTOR pathway in HL result in decreased protein synthesis and cell cycle arrest, as well as in decreased angiogenesis. Everolimus has shown preliminary evidence of efficacy as a single-agent in heavily pretreated relapsed/refractory HL, with an overall fair safety profile. The purpose of this review is to discuss the employment of everolimus as an antiproliferative and antiangiogenic agent in HL and to report the critical role of the mTOR pathway and angiogenesis in this malignancy.
Export Options
About this article
Cite this article as:
Guarini A., Minoia C., Giannoccaro M., Rana A., Iacobazzi A., Lapietra A., Raimondi A., Silvestris N., D. Gadaleta C. and Ranieri G., mTOR as a Target of Everolimus in Refractory/Relapsed Hodgkin Lymphoma, Current Medicinal Chemistry 2012; 19 (7) . https://dx.doi.org/10.2174/092986712799320727
DOI https://dx.doi.org/10.2174/092986712799320727 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Classification and Drug Response Prediction in Cancer
Current Drug Targets Targeting Tumors Using Estrogen Receptor Ligand Conjugates
Current Cancer Drug Targets Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Fertility Preservation in Women After the Cancer
Current Pharmaceutical Design The Tree of Sirtuins and the Garden of Cardiovascular Youth
Current Vascular Pharmacology RBM15 Functions in Blood Diseases
Current Cancer Drug Targets The Use of Temozolomide for the Treatment of Malignant Tumors: Clinical Evidence and Molecular Mechanisms of Action
Recent Patents on Anti-Cancer Drug Discovery Ubiquitin Ligases as Key Elements for the Modulation of the Immune Response: An Insight in the Pathogenesis of Autoimmunity
Current Rheumatology Reviews A Therapeutic Potential of Animal β-hairpin Antimicrobial Peptides
Current Medicinal Chemistry Cannabis Phenolics and their Bioactivities
Current Medicinal Chemistry Lipoxygenase Inhibitors as Cancer Chemopreventives: Discovery, Recent Developments and Future Perspectives
Current Medicinal Chemistry Isoform Characterisation, Heterologous Expression and Functional Analysis of Two Lectins from Vatairea macrocarpa
Protein & Peptide Letters Different Concepts of Drug Delivery in Disease Entities
Mini-Reviews in Medicinal Chemistry Targeting Metabolic Enzymes in Cancer – Clinical Trials Update
Current Enzyme Inhibition Oxidised Products of Cholesterol: Their Role in Apoptosis
Current Nutrition & Food Science Multi-modal Anti-cancer Activities Provided by a Non-replicating Sendai Virus Envelope
Current Cancer Therapy Reviews Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol Derivatives
Mini-Reviews in Medicinal Chemistry Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets A Role of DEAD-Box RNA Helicase rck/p54 in Cancer Cells
Current Drug Therapy Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets